| Nobuhiko Kira, MD | |
|
19917 7th Ave Ne Ste 205, Poulsbo, WA 98370-6555 | |
| (360) 779-1963 | |
| (360) 779-6449 |
| Full Name | Nobuhiko Kira |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 21 Years |
| Location | 19917 7th Ave Ne Ste 205, Poulsbo, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285786772 | NPI | - | NPPES |
| 8505547 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD00048453 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
News Archive
The 66th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada. Leading international and Canadian experts will meet to discuss the latest knowledge and advances in women's health and in the practice of obstetrics and gynaecology.
Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.
A recent study by researchers from the National University of Singapore found that when it comes to making financial decisions under risk, older adults will regard the financial outcomes of others' as their own and make choices that they would have selected for themselves.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040220000099 |
News Archive
The 66th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada. Leading international and Canadian experts will meet to discuss the latest knowledge and advances in women's health and in the practice of obstetrics and gynaecology.
Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.
A recent study by researchers from the National University of Singapore found that when it comes to making financial decisions under risk, older adults will regard the financial outcomes of others' as their own and make choices that they would have selected for themselves.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nobuhiko Kira, MD Po Box 960, Bremerton, WA 98337-0212 Ph: (360) 478-2366 | Nobuhiko Kira, MD 19917 7th Ave Ne Ste 205, Poulsbo, WA 98370-6555 Ph: (360) 779-1963 |
News Archive
The 66th Annual Clinical Meeting of the Society of Obstetricians and Gynaecologists of Canada. Leading international and Canadian experts will meet to discuss the latest knowledge and advances in women's health and in the practice of obstetrics and gynaecology.
Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.
A recent study by researchers from the National University of Singapore found that when it comes to making financial decisions under risk, older adults will regard the financial outcomes of others' as their own and make choices that they would have selected for themselves.
Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.
› Verified 1 days ago
Ellen K Stehouwer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 20730 Bond Rd Ne Ste 104, Poulsbo, WA 98370 Phone: 360-626-1166 | |
Kenneth R. Fabert, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 19379 7th Ave Ne, Poulsbo, WA 98370 Phone: 360-394-1000 | |
Patrick Lloyd Tracy, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 19245 7th Ave Ne, Poulsbo, WA 98370 Phone: 360-782-3500 | |
Dr. Mark C Hoffman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22180 Olympic College Way, Suite 201, Poulsbo, WA 98370 Phone: 360-394-3500 Fax: 360-394-3501 | |
Dr. Craig Duncan Karr, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 19245 7th Ave Ne, Poulsbo, WA 98370 Phone: 360-782-3500 | |
Gabriela Cash, MD, MBA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 19980 10th Ave Ne Ste 202, Poulsbo, WA 98370 Phone: 360-979-0569 Fax: 877-805-9505 |